Enodia Therapeutics moves into The HIVE Innovation Centre to accelerate the development of its targeted therapy programmes
Villejuif, 26/03/2026 – Kadans Science Partner announces the arrival of Enodia Therapeutics at the Innovation Centre of The HIVE, its building of laboratories and office spaces dedicated to the life sciences, located on the Campus Grand Parc in Villejuif.
Developing new therapeutic options for complex diseases
Enodia Therapeutics is developing targeted therapies aimed at proteins that have so far been difficult to address, particularly in oncology and inflammatory diseases. Its approach is based on modulating the Sec61 complex to block or induce the degradation of proteins involved in disease as early as their synthesis, paving the way for innovative therapeutic strategies. Founded in 2025 from research carried out at the Institut Pasteur and incubated by the Argobio Studio start-up studio, the company raised €20.7 million in seed funding in 2026 from investors including Elaia, Pfizer Ventures, and Bpifrance, to accelerate the development of its platform and its first preclinical programmes.
A setting designed to support early-Stage Biotechs
The HIVE Innovation Centre has been designed to meet the specific needs of start-ups and young biotechnology companies, offering them fitted-out and fully equipped laboratory and office spaces under a flexible service agreement.This model allows start-ups to strengthen their visibility and engage in a full growth trajectory within the ecosystem.
A location within a major scientific ecosystem
Situated on the Campus Grand Parc in Villejuif, The HIVE forms part of an ecosystem renowned for excellence in oncology and life sciences, near leading hospitals, research institutes, and academic partners. This strategic location provides Enodia Therapeutics with privileged access to a dense scientific and clinical network, conducive to the development of translational research projects.
“Our move into The HIVE marks an important milestone for Enodia Therapeutics. This environment enables us to accelerate our activities and progress efficiently towards the preclinical stages of our programmes,” says Yves Ribeill, CEO of Enodia Therapeutics.
“The arrival of Enodia Therapeutics further strengthens the ecosystem of The HIVE Innovation Centre,” explains Sandrine Lo, Investment & Asset Manager at Kadans Science Partner. “We are proud to host the team during this first phase of independence and hope to support them through their next stages of growth. We wish them every success for the future.”
More info about the Innovation Center
More info about Enodia Therapeutics
More info about Campus Grand Parc
